NTRK CONNECT partnered with NTRKers on a poster tour at ESMO 2022. Led by Prof. David Hong, the tour provided patients and caregivers an opportunity to better understand the latest TRK fusion-positive cancer data, with a particular emphasis on lung cancer.
Video summaries of 2 abstracts from ESMO 2022 and 1 abstract from WCLC 2022 are available to view now.
The three posters covered are:
- Poster 1 - Larotracking - Real life study of locally advanced/metastatic solid tumor treated with larotrectinib in French expanded access program (Dufresne A. et al)
- Poster 2 - Efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase fusion cancer with an extended follow-up (McDermott R. et al)
- Poster 3 - Extended follow-up of efficacy and safety of larotrectinib in patients with TRK fusion lung cancer (Moreno V. et al)